Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 16848
Country/Region: Nigeria
Year: 2016
Main Partner: Caritas Internationalis
Main Partner Program: Catholic Caritas Foundation of Nigeria (CCFN)
Organizational Type: Implementing Agency
Funding Agency: HHS/CDC
Total Funding: $6,428,971 Additional Pipeline Funding: $4,311,422

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $2,598,988
Care: Orphans and Vulnerable Children (HKID) $1,672,818
Care: TB/HIV (HVTB) $0
Care: Pediatric Care and Support (PDCS) $372,483
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $405,907
Testing: HIV Testing and Counseling (HVCT) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $0
Treatment: Adult Treatment (HTXS) $1,138,303
Treatment: Pediatric Treatment (PDTX) $240,472
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 583
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 187
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 651
GEND_GBV Number of people receiving post-GBV care 2017 838
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 19,750
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 17,517
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 207,612
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 129,354
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 374,233
HTS_TST Service Delivery Point (Facility): Index testing 2017 662
HTS_TST Service Delivery Point (Facility): Inpatient 2017 663
HTS_TST Service Delivery Point (Facility): Malnutrition facilities 2017 350
HTS_TST Service Delivery Point (Facility): Other PITC 2017 37
HTS_TST Service Delivery Point (Facility): Outpatient 2017 193,154
HTS_TST Service Delivery Point (Facility): Pediatric 2017 37,265
HTS_TST Service Delivery Point (Facility): PMTCT 2017 61,726
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 7,947
HTS_TST Service Delivery Point (Facility): VCT 2017 71,552
HTS_TST Service Delivery Point (Facility): VMMC 2017 877
HTS_TST Sum of Aggregated Age/Sex <15 2017 37,267
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 336,966
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 374,233
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 600
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 475
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 6,757
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 5,146
LAB_PT CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 21
LAB_PT CD4: Number of laboratories that participate in this PT program 2017 23
LAB_PT CD4: Number of laboratories that perform this testing 2017 23
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 25
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2017 28
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2017 28
OVC_SERV Age/Sex: 18+ Female 2017 1,752
OVC_SERV Age/Sex: 18+ Male 2017 1,747
OVC_SERV By Aggregated Age/Sex: <18 Female 2017 15,750
OVC_SERV By Aggregated Age/Sex: <18 Male 2017 15,750
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2017 34,999
OVC_SERV Sum of Age/Sex disaggregates 2017 3,499
PMTCT_ART Already on ART at beginning of current pregnancy 2017 851
PMTCT_ART New on ART 2017 1,239
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 61,743
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 1,580
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 529
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 5
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 20
PMTCT_EID Sum of Infant Age disaggregates 2017 2,109
PMTCT_STAT By: Known positives at entry 2017 1,187
PMTCT_STAT By: Number of new positives identified 2017 1,012
PMTCT_STAT Number of new ANC and L&D clients 2017 64,997
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 61,743
PMTCT_STAT Sum of Positives Status disaggregates 2017 2,199
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 11
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 252
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 7
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 216
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 536
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 486
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 1,662
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 3
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 1,494
TB_SCREENDX Screen Result: Screened Positive for TB 2017 1,846
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 55,254
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 20,066
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 2,494
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 2,454
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 80,268
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 52
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 1,143
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 71
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 1,568
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 2,834
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 3,150
TX_CURR Aggregated Age/Sex: <15 Female 2017 2,618
TX_CURR Aggregated Age/Sex: <15 Male 2017 2,585
TX_CURR Aggregated Age/Sex: 15+ Female 2017 44,874
TX_CURR Aggregated Age/Sex: 15+ Male 2017 16,277
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 66,354
TX_CURR Sum of Aggregated Age/Sex <15 2017 5,203
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 61,151
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 66,354
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 419
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 370
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 6,110
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 5,424
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 12,323
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 12,323
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 66,354
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 59,716
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 1,873
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 1,833
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 41,090
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 14,920
TX_PVLS Numerator: Indication: Routine 2017 47,775
TX_PVLS Numerator: Indication: Targeted 2017 11,941
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 2,081
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 2,039
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 45,659
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 16,575
TX_PVLS_den Denominator: Indication: Routine 2017 53,084
TX_PVLS_den Denominator: Indication: Targeted 2017 13,270
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 463
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 455
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 10,626
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 3,930
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 15,474
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 18,205
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 542
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 539
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 12,507
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 4,617
Cross Cutting Budget Categories and Known Amounts Total: $845,722
Food and Nutrition: Commodities $142,000
Economic Strengthening $250,000
Gender: Gender Based Violence (GBV) $372,328
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Gender: Gender Equality $40,000
Changing harmful gender norms and promoting positive gender norms
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Promoting gender-related policies and laws that increase legal protection
Increase gender-equitable access to income and productive resources, including education
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Equity in HIV prevention, care, treatment and support
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Water $41,394